Acorda Names CMO
Acorda Therapeutics Inc., a company focused on neurological disorders, has appointed Burkhard Blank chief medical officer (CMO) – effective immediately. Blank was appointed as the company’s interim CMO in January 2016 and has previous experience of serving as CMO for various biopharmaceutical companies including Boehringer Ingelheim GMBH. Blank has also been a strategic advisor to several biotechnology companies.
You may also be interested in...
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.